Адъювантная внутрипузырная химиотерапия поверхностного рака мочевого пузыря

1. Soloway M.S., Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer. 1980;46(5):1158—63.

2. Hirao Y., Okajima E., Ohara S. et al. Prophylactic treatment for superficial bladder cancer following transurethral resection. Cancer Chemother Pharmacol 1987;20 (Suppl):S85—90.

3. Elmer A., Bermes U., Drath L. et al. Sepsis and multiple organ failure after BCG-instillation for bladder cancer. Internist (Berl) 2004;45(8):935—9.

4. Carballido J., Molto L.M., Olivier D.P. et al. Analysis of the effect of intravesical treatment with interfero-a-2b on clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors. Anti-Cancer Drugs 1992; 3(Suppl1): 9—12.

5. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., Вердана; 2001.

6. Heijden A.G. van der, Witjes J.A. Future strategies in the diagnosis, staging and treatment of bladder cancer. Curr Opin Urol 2003;13(5):389—95.

7. Shelley M.D., Court J.B., Kynaston H. et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003;(3):CD003231.

8. Soulie M., Straub M., Game X. et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol 2002;167(3):1325—8.